These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161 [No Abstract] [Full Text] [Related]
6. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?]. Wedekind S MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622 [No Abstract] [Full Text] [Related]
7. [Problem in prolonged levodopa administration of Parkinson disease patients--from the standpoint of the autonomic nervous function]. Matsui TA; Nishikawa S; Saigo K; Kihara M; Takahashi M Rinsho Shinkeigaku; 1998 Apr; 38(4):295-300. PubMed ID: 9742874 [TBL] [Abstract][Full Text] [Related]
8. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution. Schelosky L; Poewe W Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415 [TBL] [Abstract][Full Text] [Related]
16. Strategies in the treatment of early Parkinson's disease. Rinne UK Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417 [TBL] [Abstract][Full Text] [Related]
17. Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa. Lammers GJ; Roos RA Lancet; 1993 Aug; 342(8868):439. PubMed ID: 8101938 [No Abstract] [Full Text] [Related]
18. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Avanzi M; Uber E; Bonfà F Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629 [TBL] [Abstract][Full Text] [Related]